Novartis gets FDA approval for Kisqali to treat early breast cancer
The FDA approval is based on results from the Phase 3 NATALEE trial, in which Kisqali plus endocrine therapy (ET) showed a significant and clinically meaningful reduction in the risk...
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry